Home » Newsletters » BioWorld Science

BioWorld Science

May 5, 2005

View Archived Issues

Series A financing at Actimis

FLT3 tyrosine kinase inhibitor eradicates tumors in mice

JUN-1111 inhibits Cdc25 by selective and irreversible oxidation

NGF gene therapy shows promise in the treatment of Alzheimer's disease

Promising phase II data reported for P1A in the prevention of antibiotic resistance

Activation of PKC-delta with PEP-005 results in antileukemic effects in vitro

Exelixis submits IND for XL-844

YM BioSciences completes purchase of Delex Therapeutics

Roche makes milestone payment to retain option to MEM-3454

Extension of Metabolex and Astellas' diabetes and obesity collaboration

New therapies for neurological disorders claimed in recent patent literature

Novel HIV reverse transcriptase inhibitors emerge from Gilead R&D

Novel antithrombotic therapies claimed by Arena, Yamanouchi and Rovi

Large Scale Biology seeks orphan drug status for lysosomal acid lipase product

Preliminary data on the efficacy of Flurizan in Alzheimer's disease

European orphan drug designation for ambrisentan

Improved tocolytic effects found for barusiban in a model of preterm labor

Priority review for Increlex NDA

New follow-on phase II study of M-40403 and morphine in postsurgical pain

Enrollment begins for phase II prostate cancer trial of AP-23573

Endovasc discusses Liprostin with the FDA

Helix identifies lead product candidate from DOS-47 cancer therapeutic program

InKine submits NDA for next generation purgative product

Botulinum toxin type A demonstrates potential in chronic daily headache

Boostrix receives FDA approval

Prous Science expands webcast coverage of the 2005 FDA Science Forum

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...